Other Events ·
On July 29, 2026, the Emirates Drug Establishment granted marketing authorization for ANKTIVA in the United Arab…
IBRXImmunityBio, Inc.
On July 29, 2026, the Emirates Drug Establishment granted marketing authorization for ANKTIVA in the United Arab Emirates across two indications: BCG-unresponsive non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. This approval expands ANKTIVA's global regulatory footprint to 34 countries, making the UAE the fifth jurisdiction to authorize the therapy. The filing details clinical evidence from trials QUILT-3.032 and QUILT-3.055 supporting these indications. ImmunityBio operates in the biotechnology industry, focusing on developing immunotherapies for cancer.